Search Result

Results for "

P-glycoprotein (P-gp)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P-glycoprotein (60) AMPK (1) Antibiotic (2) Apoptosis (6) BCRP (6) c-Met/HGFR (2) Calcium Channel (10) Cytochrome P450 (11) Drug Metabolite (3) Endogenous Metabolite (5) HIV (5) HIV Protease (5) iGluR (1) Isotope-Labeled Compounds (6) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) NF-κB (1) Parasite (2) PPAR (1) Reactive Oxygen Species (1) SARS-CoV (5) TAM Receptor (2)
By Research Areas:	Cancer (56) Cardiovascular Disease (8) Infection (7) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Glycoprotein VI P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-U00247

MCI826

P-glycoprotein Cancer

MCI826 is a P-glycoprotein (P-gp) antagonist.
HY-146117

P-gp modulator 2

P-glycoprotein Cancer

P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .
HY-146118

P-gp modulator 3

P-glycoprotein Cancer

P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

MCI826	P-glycoprotein	Cancer
MCI826 is a *P-glycoprotein* (P-gp) antagonist.

P-gp modulator 2	P-glycoprotein	Cancer
P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric **P-glycoprotein (P-gp)** modulator .

P-gp modulator 3	P-glycoprotein	Cancer
P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric **P-glycoprotein (P-gp)** modulator .

HY-144366

P-gp inhibitor 3	P-glycoprotein	Cancer
P-gp inhibitor 3 is an effective *P-glycoprotein* (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a *p-glycoprotein* inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-112912

P-gp modulator 1	P-glycoprotein	Cancer
P-gp modulator 1 is a high affinity, orally available modulator of **P-glycoprotein (Pgp)*, can reverse the Pgp*-mediated multidrug resistance ((MDR) .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-10550A

Tariquidar methanesulfonate, hydrate Maximum Cited Publications 46 Publications Verification XR9576 methanesulfonate, hydrate	P-glycoprotein	Cancer
Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent and specific inhibitor of *P-glycoprotein* (P-gp) with a K_d of 5.1 nM.

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-N0425

Epoxylathyrol	P-glycoprotein	Cancer
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a **P-glycoprotein (P-gp)** inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-10550

Tariquidar Maximum Cited Publications 46 Publications Verification XR9576	P-glycoprotein	Cancer
Tariquidar (XR9576) is a potent and specific inhibitor of *P-glycoprotein* (P-gp) with the high affinity (K_d=5.1 nM) .

HY-110377

Tariquidar dihydrochloride XR9576 dihydrochloride	P-glycoprotein	Cancer
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of *P-glycoprotein* (P-gp) with the high affinity (K_d=5.1 nM) .

HY-W009141

1-Monopalmitin

Glyceryl palmitate
P-glycoprotein Cancer

1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

1-Monopalmitin Glyceryl palmitate	P-glycoprotein	Cancer
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N10562

Mutabilol	P-glycoprotein	Cancer
Mutabilol (compound 1) is a potent **p-glycoprotein (P-gp)** regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-155032

P-gp inhibitor 15	P-glycoprotein	Cancer
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective *P-glycoprotein* modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-100750

Norverapamil hydrochloride 1 Publications Verification (±)-Norverapamil hydrochloride; D591 hydrochloride	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a **P-glycoprotein (P-gp)** function inhibitor .

HY-135328

Norverapamil (±)-Norverapamil; D591	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a **P-glycoprotein (P-gp)** function inhibitor .

HY-162369

PID-9	P-glycoprotein	Cancer
PID-9 is a *P-glycoprotein* inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC₅₀ = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .

HY-150565

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent **P-glycoprotein (P-gp)** inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In ^TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .

HY-N1941

Isosinensetin

Isosinensetin, a polymethoxylated flavone extracted from pericarpium citri reticulatae viride, exhibits inhibition on P-glycoprotein (P-gp) in MDR1-MDCKII cells .

Isosinensetin
Isosinensetin, a polymethoxylated flavone extracted from pericarpium citri reticulatae viride, exhibits inhibition on **P-glycoprotein (P-gp)** in MDR1-MDCKII cells .

HY-B0777

Moxidectin 1 Publications Verification CL301423	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-N6932

Voacamine
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits *P-glycoprotein* (P-gp) action in multidrug-resistant tumor cells .

HY-50671

Zosuquidar trihydrochloride 10+ Cited Publications RS 33295-198 trihydrochloride; LY-335979 trihydrochloride	P-glycoprotein	Cancer
Zosuquidar (LY335979) trihydrochloride is a *P-glycoprotein* (P-gp) inhibitor (K_i=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-15255

Zosuquidar 10+ Cited Publications RS 33295-198; LY-335979	P-glycoprotein	Cancer
Zosuquidar (LY335979) is a *P-glycoprotein* (P-gp) inhibitor (K_i=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-135328AS

Norverapamil-d7 hydrochloride (±)-Norverapamil-d₇ (hydrochloride); D591-d7 (hydrochloride)	Calcium Channel	Cardiovascular Disease
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-135328S

Norverapamil-d7 (±)-Norverapamil-d₇; D591-d₇	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a *P-gp* inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-N4108

Hypophyllanthin	P-glycoprotein	Inflammation/Immunology Cancer
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits **P-glycoprotein (P-gp)** activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-50880

Elacridar hydrochloride 20+ Cited Publications GF120918A	P-glycoprotein BCRP	Cancer
Elacridar hydrochloride (GF120918A) is an orally active **P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)** inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-B0777R

Moxidectin (Standard) CL301423 (Standard)	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (Standard) is the analytical standard of Moxidectin. This product is intended for research and analytical applications. Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-113805

MC70	P-glycoprotein	Cancer
MC70 is a potent and non-selective **P-glycoprotein (P-gp) inhibitor with an EC₅₀ of 0.69 µM. MC70 is an ABC transporters** inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1 .

HY-101791

P-gp inhibitor 1

P-glycoprotein Cancer

P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

P-gp inhibitor 1	P-glycoprotein	Cancer
P-gp inhibitor 1 is a novel inhibitor reversing *P-glycoprotein*-mediated multidrug resistance.

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum **P-glycoprotein (P-gp)** inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-19626

NSC23925

P-glycoprotein Cancer

NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.

NSC23925	P-glycoprotein	Cancer
NSC23925 is a novel, selective and effective *P-glycoprotein* (Pgp) inhibitor.

HY-A0064

Verapamil hydrochloride 40+ Cited Publications (±)-Verapamil hydrochloride; CP-16533-1 hydrochloride	Calcium Channel P-glycoprotein Cytochrome P450	Cardiovascular Disease
Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation **P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4**. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275

Verapamil 40+ Cited Publications (±)-Verapamil; CP-16533-1	Calcium Channel P-glycoprotein Cytochrome P450	Metabolic Disease Cancer
Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation **P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4**. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-146096

RMS3	P-glycoprotein Apoptosis	Cancer
RMS3, a tetrandrine analogue, is a potent **P-glycoprotein (P-gp) inhibitor. RMS3 has markedly antiproliferative and cytotoxic effects on cancer cells. RMS3 causes PARP cleavage, a marker for cells undergoing apoptosis**. RMS3 has strong anticancer property .

HY-149277

FM04	P-glycoprotein	Cancer
FM04 is a potent *P-glycoprotein* (P-gp) inhibitor (EC₅₀=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .

HY-17013

Dofequidar

P-glycoprotein Cancer

Dofequidar(MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.

Dofequidar	P-glycoprotein	Cancer
Dofequidar(MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.

HY-16397

Phenformin Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis	Metabolic Disease Cancer
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .

HY-149053

OY-101	P-glycoprotein	Cancer
OY-101 is an orally active, potent and specific **P-glycoprotein (P-gp)** inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific *P-glycoprotein* (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-132866

YS-370	P-glycoprotein	Cancer
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity .

HY-A0064S

Verapamil-d3 hydrochloride (±)-Verapamil-d₃ hydrochloride; CP-16533-1-d₃ hydrochloride	Isotope-Labeled Compounds Calcium Channel P-glycoprotein Cytochrome P450	Cardiovascular Disease
Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

HY-132189

Laniquidar R101933	P-glycoprotein	Cancer
Laniquidar (R101933) is a noncompetitive, third generation **P-glycoprotein (P-gp) inhibitor with an IC₅₀** of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters . Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . Laniquidar has limited oral bioavailability .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	P-glycoprotein	Cancer
8α,9α-Epoxycoleon-U-quinone (compound 3) is a **p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp** activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W009141

1-Monopalmitin Glyceryl palmitate	Source classification Plants	P-glycoprotein
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N4108

Hypophyllanthin	Phyllanthus urinaria Linn. Structural Classification Classification of Application Fields Source classification Lignans Euphorbiaceae Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	P-glycoprotein
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits **P-glycoprotein (P-gp)** activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-N0425

Epoxylathyrol	Structural Classification Classification of Application Fields Euphorbia boetica Terpenoids Source classification Diterpenoids Euphorbiaceae Plants Disease Research Fields Cancer	P-glycoprotein
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a **P-glycoprotein (P-gp)** inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-N10562

Mutabilol	Terpenoids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Diterpenoids Plants	P-glycoprotein
Mutabilol (compound 1) is a potent **p-glycoprotein (P-gp)** regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
8α,9α-Epoxycoleon-U-quinone (compound 3) is a **p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp** activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of **P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of **P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-N2453

Convallatoxin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants Inflammation/Immunology Disease Research Fields	PPAR NF-κB P-glycoprotein
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-N2103

Tenacissoside G	Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Steroids Cancer	P-glycoprotein
Tenacissoside G is a C21 steroid from the stems of Marsdenia tenacissima. Tenacissoside G reverses multidrug resistance in P-glycoprotein (Pgp)-overexpressing multidrug-resistant cancer cells .

HY-126940

Furanodiene	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Curcuma longa Disease Research Fields Cancer Zingiberaceae	Reactive Oxygen Species P-glycoprotein Apoptosis
Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae. Furanodiene plays anti-cancer effects through anti-angiogenesis and inducing ROS production, DNA strand breaks and apoptosis. Furanodiene suppresseed efflux transporter *Pgp* (P-glycoprotein) function and reduced Pgp protein level .

HY-N6684

Deoxynivalenol 4 Publications Verification Vomitoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Others
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N3028

Taccalonolide B	Structural Classification Classification of Application Fields Source classification Schizocapsa plantaginea Hance Plants Disease Research Fields Taccaceae Steroids Cancer	Microtubule/Tubulin
Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC₅₀ of 208 nM .

HY-N2416

Taccalonolide A	Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Tacca chantrieri Andre Taccaceae Steroids Cancer	Microtubule/Tubulin Apoptosis
Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities . Taccalonolide A causes G₂-M accumulation, Bcl-2 phosphorylation and initiation of apoptosis . Taccalonolide A is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug resistance protein 7 (MRP7), with an IC₅₀ of 622 nM for SK-OV-3 cells .

Cat. No.	Product Name	Chemical Structure

HY-135328AS

Norverapamil-d7 hydrochloride
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-A0064S

Verapamil-d3 hydrochloride

Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

HY-A0064S1

Verapamil-d6 hydrochloride

Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-135328S

Norverapamil-d7
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-14275S1

Verapamil-d7
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation **P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4**. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks